High Incidence and prevalence rate of Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is very common in adults which accounts for 80 percent of cases. In the United States (U.S.) the cases of AML ranges from three to five cases per 100000 population. According to a Cancer statistics in 2015 there are 20830 new cases that are diagnosed and 10,000 are died from this disease. Increasing expenditure on healthcare. Increasing expenditure on healthcare according to new data from the centers on Medicare and Medicaid Services U.S. Spent $3.2 trillion on healthcare in 2015.
Additionally, increasing investment in Research and development (R&D) and advancement in pharmacology and molecular biology to promote drug development are also driving the Global Acute Myeloid Therapeutics Market.
Complications related to chemotherapy
Chemotherapy treats various types of cancer. But also causes side effects differently in different patients at different locations and thus highly depend on the type of cancer, location of the cancer, drugs and their dose and general health of the individual. Common side effects of chemotherapy headaches, muscle pain, stomach pain and pain from nerve damage that is burning and numbness.
Additionally, stringent regulatory guidelines of government in the different regions for these therapeutics is restraining the global acute myeloid leukemia therapeutics market.
North America to Dominate the Market
The Global Acute Myeloid Leukemia Therapeutics market is segmented into chemotherapy and by geography. The chemotherapy segment includes CALGB 8811 regimen, hyper - CVAD regimen, Oncaspar, linker regimen, nucleoside inhibitors, and others. Geographically the market has been segmented into North America, Europe, Asia-Pacific, the Middle East & Africa and South America.
North America is dominating the acute myeloid leukemia therapeutics market due to rising incidence of acute myeloid leukemia therapeutics, rise in the healthcare expenditure in that region, high investment in the development of the pipeline drugs and awareness among the people for the treatment of the acute myeloid leukemia therapeutics. Asia Pacific is expected to be the fastest growing region over the forecast period.
Key Developments in the Market
- June 2017: Genmab received US FDA approval for the Darzalex for the relapsed or refractory multiple myeloma.
Reasons to Purchase this Report
- Current and future Acute Myeloid Leukemia Market outlook in the developed and emerging markets
- Analyzing various perspectives of the market with the help of Porter’s five forces analysis
- The treatment type that is expected to dominate the market
- Regions that are expected to witness fastest growth during the forecast period
- Identify the latest developments, market shares and strategies employed by the major market players.
- 3 months analyst support along with the Market Estimate sheet in excel.
This report can be customized to meet your requirements..
1.1 MARKET DEFINITION
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. KEY INFERENCES
5. MARKET OVERVIEW
5.1 CURRENT MARKET SCENARIO
5.2 PORTERS FIVE FORCES
5.2.1 BARGAINING POWER OF SUPPLIERS
5.2.2 BARGAINING POWER OF CONSUMERS
5.2.3 THREATS OF NEW ENTRANTS
5.2.4 THREAT OF SUBSTITUTE PRODUCT AND SERVICES
5.2.5 COMPETITIVE RIVALRY WITHIN THE INDUSTRY
6. DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC)
6.1 MARKET DRIVERS
6.1.1 HIGH INCIDENCE AND PREVALENCE RATE OF ACUTE MYELOID LEUKEMIA
6.1.2 INCREASING INVESTMENT IN RESEARCH AND DEVELOPMENT (R&D)
6.1.3 ADVANCEMENT IN PHARMACOLOGY AND MOLECULAR BIOLOGY TO PROMOTE DRUG DEVELOPMENT
6.2 MAARKET RESTRAINT
6.2.1 COMPLICATIONS RELATED TO CHEMOTHERAPY
6.2.2 STRINGENT REGULATORY GUIDELINES OF GOVERNMENT
6.4 KEY CHALLENGES
7. MARKET SEGMENTATION
7.1 BY CHEMOTHERAPY
7.1.2 ANTHRACYCLINE DRUGS
7.1.3 ALKYLATING AGENTS
7.1.5 TYROSINE KINASE INHIBITORS
126.96.36.199 DASATINIB (SPRYCEL)
188.8.131.52 IMATINIB (GLEEVEC)
7.1.6 HORMONAL THERAPY
7.2 SEGEMENTATION BY GEOGRAPHY
7.2.1 NORTH AMERICA
184.108.40.206 UNITED STATES
220.127.116.11 UNITED KINGDOM
18.104.22.168 REST OF EUROPE
22.214.171.124 AUSTRALIA & NEW ZEALAND
126.96.36.199 SOUTH KOREA
188.8.131.52 REST OF ASIA-PACIFIC
7.2.4 MIDDLE EAST AND AFRICA
184.108.40.206 SOUTH AFRICA
220.127.116.11 REST OF MIDDLE EAST AND AFRICA
7.2.5 SOUTH AMERICA
18.104.22.168 REST OF SOUTH AMERICA
8. COMPETITIVE LANDSCAPE
8.1 MERGERS AND ACQUISITION ANALYSIS
8.2 AGREEMENTS, COLLABORATIONS & PARTNERSHIPS
8.3 NEW PRODUCTS LAUNCHES
9. COMPANY PROFILES
9.1 GENMAB A/S
9.3 BRISTOL MYER SQUIBB
9.4 NOVARTIS AG
9.6 CELEGENE CORPORATION
9.7 EISAI CO LTD
9.8 CLAVIS PHARMA
9.9 AMBIT BIOSCIENCE CORPORATION
10. FUTURE OUTLOOK OF THE MARKET